Crawford Investment Counsel Inc. Has $2.55 Million Stake in Nu Skin Enterprises, Inc. (NUS)

Share on StockTwits

Crawford Investment Counsel Inc. lifted its stake in shares of Nu Skin Enterprises, Inc. (NYSE:NUS) by 11.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,374 shares of the company’s stock after purchasing an additional 5,500 shares during the quarter. Crawford Investment Counsel Inc.’s holdings in Nu Skin Enterprises were worth $2,554,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Amalgamated Bank boosted its stake in shares of Nu Skin Enterprises by 14.8% during the fourth quarter. Amalgamated Bank now owns 11,484 shares of the company’s stock valued at $704,000 after acquiring an additional 1,483 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd boosted its stake in shares of Nu Skin Enterprises by 8.9% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 813,238 shares of the company’s stock valued at $49,875,000 after acquiring an additional 66,408 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Nu Skin Enterprises by 676.3% during the fourth quarter. Bank of Montreal Can now owns 69,583 shares of the company’s stock valued at $4,268,000 after acquiring an additional 60,620 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Nu Skin Enterprises by 55.4% during the fourth quarter. Squarepoint Ops LLC now owns 109,000 shares of the company’s stock valued at $6,685,000 after acquiring an additional 38,844 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Nu Skin Enterprises by 3.4% during the fourth quarter. BlackRock Inc. now owns 6,273,298 shares of the company’s stock valued at $384,741,000 after acquiring an additional 205,481 shares during the last quarter. Institutional investors and hedge funds own 77.25% of the company’s stock.

A number of analysts recently commented on the company. ValuEngine lowered Nu Skin Enterprises from a “hold” rating to a “sell” rating in a research note on Saturday, May 18th. Zacks Investment Research raised Nu Skin Enterprises from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Bank of America reissued an “underperform” rating and issued a $57.00 price target (up from $52.00) on shares of Nu Skin Enterprises in a research note on Wednesday, May 1st. Deutsche Bank raised Nu Skin Enterprises from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a research note on Wednesday, May 1st. Finally, Stifel Nicolaus lowered Nu Skin Enterprises from a “hold” rating to a “sell” rating and decreased their price target for the stock from $63.00 to $43.00 in a research note on Monday, March 25th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $73.75.

Nu Skin Enterprises stock opened at $49.78 on Monday. The stock has a market capitalization of $2.76 billion, a PE ratio of 14.14, a PEG ratio of 1.14 and a beta of 0.67. The company has a current ratio of 1.86, a quick ratio of 1.10 and a debt-to-equity ratio of 0.44. Nu Skin Enterprises, Inc. has a 12 month low of $44.36 and a 12 month high of $88.68.

Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings data on Tuesday, April 30th. The company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.06. The company had revenue of $623.60 million for the quarter, compared to the consensus estimate of $615.98 million. Nu Skin Enterprises had a return on equity of 26.81% and a net margin of 4.82%. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the business posted $0.79 EPS. On average, equities analysts forecast that Nu Skin Enterprises, Inc. will post 3.92 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Friday, May 31st will be issued a $0.37 dividend. The ex-dividend date of this dividend is Thursday, May 30th. This represents a $1.48 dividend on an annualized basis and a dividend yield of 2.97%. Nu Skin Enterprises’s dividend payout ratio (DPR) is 42.05%.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4353962/crawford-investment-counsel-inc-has-2-55-million-stake-in-nu-skin-enterprises-inc-nus.html.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.

Featured Article: What is the Russell 2000 Index?

Want to see what other hedge funds are holding NUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nu Skin Enterprises, Inc. (NYSE:NUS).

Institutional Ownership by Quarter for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report